Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma

doi:10.3748/wjg.v22.i40.8967

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 40

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7962)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-3) series.

Item

Count

PDF

565

WORD

284

HTML

4085

Figures (1-7)

196

Tables (1-3)

173

Sum=5303

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

914

Download

1745

Sum=2659

Oct 28, 2016 (publication date) through Aug 24, 2024

Times Cited of This Article

Times Cited (42)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Oct 28, 2016; 22(40): 8967-8977
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.8967

Table 2 Patients’ characteristics

Case	Sex	Age	Etiology	Child-Pugh score (Points)	Stage¹	BCLC²	Maintenance dose (mg/kg per day)	Administration period (d)	Response	AFP (ng/mL)		DCP (mAU/mL)
Case	Sex	Age	Etiology	Child-Pugh score (Points)	Stage¹	BCLC²	Maintenance dose (mg/kg per day)	Administration period (d)	Response	Baseline	After 1 course	Baseline	After 1 course
1	M	80	HCV	B (7)	IVA	C	10	17	PD	1918	-	57	-
2	M	73	HBV	B (7)	III	C	10	35	PD	127402	260627	73	61
3	M	72	HBV	B (8)	III	B	5	248	SD	189	394	85	25
4	M	65	HBV	A (5)	IVA	C	10	28	PD	603	814	9995	16793
5	F	70	HCV	A (6)	IVA	C	15	29	PD	5580	8434	19958	15321
6	F	60	HCV	A (6)	IVA	C	15	28	PD	6172	7671	4606	2283

¹According to Liver Cancer Study Group of Japan;

²According to Barcelona Clinic Liver Cancer. HCV: Hepatitis C virus; HBV: Hepatitis B virus; AFP: Alfha-fetoprotein; DCP: Des-gamma-carboxy prothrombin. PD: Progressive disease; SD: Stable disease.

Citation: Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8967-8977
URL: https://www.wjgnet.com/1007-9327/full/v22/i40/8967.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i40.8967